Payment overview · 2025
General Payments
$181.53
23 reported records · 2 companies
Healthcare provider profile · identity verified
Nicholas A Patellis, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MADISON, AL · NPI 1366582835
Verified facts
What the public records show
CMS Open Payments records show Nicholas A Patellis, M.D. received $181.53 in general payments during 2025 across 23 reported records.
Novo Nordisk Inc accounted for 75.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $137.29 | 75.6% | 20 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.24 | 24.4% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $181.53 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $137.29 | 20 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $114.01 | 17 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $44.24 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 527 | 158 |
| Amlodipine Besylate | Amlodipine Besylate | 475 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 454 | 133 |
| Atorvastatin Calcium | Atorvastatin Calcium | 371 | 109 |
| Losartan Potassium | Losartan Potassium | 357 | 115 |
| Omeprazole | Omeprazole | 322 | 111 |
| Gabapentin | Gabapentin | 288 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 258 | 78 |
| Meloxicam | Meloxicam | 253 | 88 |
| Sertraline Hcl | Sertraline Hcl | 239 | 72 |
| Trazodone Hcl | Trazodone Hcl | 216 | 66 |
| Tramadol Hcl | Tramadol Hcl | 191 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 187 | 59 |
| Potassium Chloride | Potassium Chloride | 185 | 54 |
| Jardiance | Empagliflozin | 169 | 36 |
| Famotidine | Famotidine | 166 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 139 | 40 |
| Finasteride | Finasteride | 126 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 51 |
| Montelukast Sodium | Montelukast Sodium | 122 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 122 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 37 |
| Allopurinol | Allopurinol | 117 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 27 |
| Metformin Hcl Er | Metformin Hcl | 116 | 37 |
| Azithromycin | Azithromycin | 114 | 98 |
| Metformin Hcl | Metformin Hcl | 113 | 38 |
| Furosemide | Furosemide | 112 | 34 |
| Lisinopril | Lisinopril | 112 | 34 |
| Alprazolam | Alprazolam | 111 | 27 |
| Carvedilol | Carvedilol | 109 | 34 |
| Temazepam | Temazepam | 103 | 21 |
| Glipizide Er | Glipizide | 99 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 98 | 27 |
| Ozempic | Semaglutide | 92 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 23 |
| Eliquis | Apixaban | 89 | 26 |
| Simvastatin | Simvastatin | 84 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 37 |
| Ezetimibe | Ezetimibe | 79 | 23 |
| Spironolactone | Spironolactone | 75 | 26 |
| Bupropion Xl | Bupropion Hcl | 72 | 14 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 69 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 69 | 58 |
| Synthroid | Levothyroxine Sodium | 65 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 32 |
| Baclofen | Baclofen | 61 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 15 |
| Atenolol | Atenolol | 60 | 14 |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | suppressed |
| Clonazepam | Clonazepam | 54 | 15 |
| Pregabalin | Pregabalin | 54 | 16 |
| Rybelsus | Semaglutide | 54 | 14 |
| Cefdinir | Cefdinir | 53 | 47 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 15 |
| Lorazepam | Lorazepam | 52 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 46 |
| Torsemide | Torsemide | 50 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 14 |
| Topiramate | Topiramate | 48 | 13 |
| Telmisartan | Telmisartan | 47 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | 13 |
| Diazepam | Diazepam | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 44 | suppressed |
| Testosterone | Testosterone | 43 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 41 | 12 |
| Nifedipine Er | Nifedipine | 41 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 41 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 39 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 11 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 14 |
| Doxepin Hcl | Doxepin Hcl | 37 | 11 |
| Januvia | Sitagliptin Phosphate | 37 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | 11 |
| Prednisone | Prednisone | 37 | 20 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | 11 |
| Valacyclovir | Valacyclovir Hcl | 35 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 34 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 16 |
| Estradiol | Estradiol | 32 | 13 |
| Aripiprazole | Aripiprazole | 31 | 11 |
| Primidone | Primidone | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Nystatin | Nystatin | 30 | 21 |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 29 | 13 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 16 |
| Pitavastatin Calcium | Pitavastatin Calcium | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 15 |
| Valsartan | Valsartan | 24 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 18 |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Kerendia | Finerenone | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Invokana | Canagliflozin | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 15 |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 13 |
| Fluconazole | Fluconazole | 18 | 14 |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Trimethoprim | Trimethoprim | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Tadalafil | Tadalafil | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | 11 |
| Glipizide | Glipizide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Progesterone | Progesterone, Micronized | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Levoxyl | Levothyroxine Sodium | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Oxazepam | Oxazepam | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $181.53 · 23 records | Novo Nordisk Inc | Ozempic, REXULTI, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error